Credit Suisse analyst Richard Law downgraded Kymera Therapeutics to Neutral from Outperform with a price target of $32, down from $47, based on what he now sees as reduced odds of success for KT-474 in AD and a reduced M&A weighting.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KYMR:
- Sell these stocks now, proven algorithm says
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Kymera Therapeutics price target lowered to $35 from $50 at B. Riley
- Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
- Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline